Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Australian Clinical Labs Ltd ( (AU:ACL) ) just unveiled an announcement.
Australian Clinical Labs has provided an updated notification on its ongoing on-market share buy-back program, confirming that a total of 8,118,983 ordinary fully paid shares had been repurchased before the previous trading day. On the previous day alone, the company bought back an additional 35,643 shares, as part of a capital management initiative first announced in October 2025.
The latest filing, dated 17 April 2026, is a daily update reflecting continued execution of the buy-back first disclosed on 23 October 2025. Regular disclosures of the cumulative and daily repurchases offer investors transparency on the scale and pace of the program, which can influence earnings per share, free float, and overall market perception of the company’s valuation and capital allocation priorities.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.20 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian-listed provider of pathology and diagnostic testing services, trading under the ASX code ACL. The company operates through ordinary fully paid shares and engages in capital management initiatives, including on-market share buy-backs, to manage its capital structure and shareholder returns.
Average Trading Volume: 838,781
Technical Sentiment Signal: Sell
Current Market Cap: A$380.1M
See more insights into ACL stock on TipRanks’ Stock Analysis page.